• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SI-BONE Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/26/24 4:37:44 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care
    Get the next $SIBN alert in real time by email
    sibn-20240625
    0001459839false--12-3100014598392024-06-252024-06-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________________________________________________________________
    FORM 8-K
    ____________________________________________________________________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 25, 2024
    ____________________________________________________________________________
    SI-BONE, INC.
    (Exact name of registrant as specified in its charter)
    ____________________________________________________________________________
    Delaware 001-38701 26-2216351
    (State or other jurisdiction of
    incorporation or organization)
     (Commission
    File Number)
     (I.R.S. Employer
    Identification No.)

    471 El Camino Real
    Suite 101
    Santa Clara, CA 95050
    (Address of principal executive offices) (Zip Code)

    (408) 207-0700
    (Registrant’s telephone number, include area code)

    N/A
    (Former Name or Former Address, if Changed Since Last Report)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.0001 per shareSIBNThe Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company     ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐









    Item 3.03 Material Modifications of Rights of Security Holders.
    The information set forth in Item 5.03 below is incorporated by reference here.

    Item 5.03.    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
    On June 25, 2024, SI-BONE, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, which was filed on June 25, 2024, to add a new Article VIII to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law. The foregoing description is qualified in its entirety by the Certificate of Amendment to the Amended and Restated Certificate of Incorporation, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    A total of 36,533,535 shares of the Company’s common stock were present or represented by proxy at the Annual Meeting, which represented approximately 89% of the Company’s 41,203,980 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of April 26, 2024.

    The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for or against, as well as abstentions, for the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; (c) for or against, as well as abstentions, for the advisory vote to approve executive compensation; and (d) for or against, as well as abstentions, for the approval of the amendment to the Amended and Restated Certificate of Incorporation to limit the liability of certain of the Company's officers as permitted pursuant to recent amendments to the Delaware General Corporation Law. Broker non-votes are also reported. A more complete description of each matter is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024 (the "Proxy Statement").

    Proposal 1:     Each of the below directors proposed by the Company for election was elected by the following votes to serve until the Company’s 2027 Annual Meeting of Stockholders, or until each of their respective successors has been elected and qualified. The tabulation of votes on this matter was as follows:

    ForWithheldBroker Non-Votes
    Mika Nishimura29,705,4455,631,8591,196,231
    Thomas A. West35,195,079142,2251,196,231

    Proposal 2:    The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. The tabulation of votes on this matter was as follows:

    ForAgainstAbstainBroker
    Non-Votes
    36,333,090128,47671,9690

    Proposal 3:    The compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved on an advisory basis. The tabulation of votes on this matter was as follows:

    ForAgainstAbstainBroker
    Non-Votes
    34,726,782541,40569,1171,196,231

    Proposal 4:    The amendment to the Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law, as described in the Proxy Statement, was approved. The tabulation of votes on this matter was as follows:




    ForAgainstAbstainBroker
    Non-Votes
    29,540,5505,712,29684,4581,196,231


    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits
    Exhibit No. Description
       
    3.1 
    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company
    104Cover Page Interactive Date File (embedded within the Inline XBRL document)
    \



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
      SI-BONE, INC.
       
    Date:June 26, 2024By:/s/ Anshul Maheshwari
       Anshul Maheshwari
    Chief Financial Officer
       (Principal Financial and Accounting Officer)


    Get the next $SIBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SIBN

    DatePrice TargetRatingAnalyst
    1/27/2026$21.00Buy
    TD Cowen
    8/6/2024$27.00 → $19.00Buy
    Needham
    3/28/2024$25.00Overweight
    Piper Sandler
    10/12/2022$20.00Buy
    Jefferies
    4/7/2022$34.00Overweight
    Cantor Fitzgerald
    3/1/2022$30.00 → $28.00Overweight
    Morgan Stanley
    1/18/2022$43.00 → $36.00Buy
    B of A Securities
    12/21/2021$35.00 → $30.00Buy
    Truist Securities
    More analyst ratings

    $SIBN
    SEC Filings

    View All

    SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - SI-BONE, Inc. (0001459839) (Filer)

    2/23/26 4:11:55 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.

    SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    2/17/26 6:30:45 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.

    SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    2/13/26 9:51:19 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Smith+Nephew signs distribution agreement with SI-BONE

    Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients  Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share

    2/23/26 4:30:00 PM ET
    $SIBN
    $SNN
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

    Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r

    2/23/26 4:09:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

    SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect

    2/17/26 4:30:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on SI-BONE with a new price target

    TD Cowen initiated coverage of SI-BONE with a rating of Buy and set a new price target of $21.00

    1/27/26 8:49:24 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on SI-BONE with a new price target

    Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously

    8/6/24 8:40:50 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on SI-BONE with a new price target

    Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00

    3/28/24 7:47:33 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Recupero Anthony J sold $324,204 worth of shares (21,049 units at $15.40), decreasing direct ownership by 8% to 243,418 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:52:05 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. was granted 78,294 shares and sold $318,642 worth of shares (20,756 units at $15.35), increasing direct ownership by 25% to 285,974 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:16:03 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Francis Laura was granted 229,481 shares and sold $1,432,122 worth of shares (93,475 units at $15.32), increasing direct ownership by 33% to 544,369 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:15:17 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Leadership Updates

    Live Leadership Updates

    View All

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

    Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help

    12/14/21 8:00:00 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

    SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa

    4/19/21 7:00:49 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

    SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 6:27:27 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SI-BONE Inc.

    SC 13G - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 4:43:38 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SI-BONE Inc.

    SC 13G - SI-BONE, Inc. (0001459839) (Subject)

    11/8/24 12:14:44 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $SIBN
    Financials

    Live finance-specific insights

    View All

    SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

    Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r

    2/23/26 4:09:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

    SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect

    2/17/26 4:30:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

    SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the "Investors" section of the company's websi

    2/2/26 4:30:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care